MP15-08 CANNABINOIDS REDUCE CHRONIC PROSTATITIS AND CHRONIC PELVIC PAIN SYNDROME BY MODULATING TLR-4/NF-KB SIGNALING PATHWAY
INTRODUCTION AND OBJECTIVE:
The purpose of this study was to assess the effect and investigate the mechanism of cannabinoids on LPS-induced inflammation in RWPE-1 cells and dihydrotestosterone-induced prostatitis rat model.
RWPE-1 cells were randomly divided into five groups: (a) RWPE-1 group (normal control), (b) LPS group (lipopolysaccharide-induced inflammation) and (c) CBD group (LPS-induced RWPE-1 treated by Cannabidiol), (d) CBC group (LPS-induced RWPE-1 treated by Cannabichromene), (e) CBG group (LPS-induced RWPE-1 treated by Cannabigerol). Also prostatitis rat models were diveided into two groups: (f) CBD treated group, (g) placebo group. After administration of cannabinoids therapy, cells were collected for immunofluorescence and cells were taken from the supernatant for Western blot analysis.
Three cannabinoids improved cellular inflammation in RWPE-1 by attenuating inflammation (p<0.01). Also, CBD improved Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) in rats when evaluated by von frey filaments exam. Cannabinoids reduced cyclooxygenase 2 (COX-2) expression by inhibiting the TLR4-NFκB pathway compared with the LPS group with in vitro prostatitis (p<0.05). TRAF2 mediates the ERK1/2-COX2 pathway.
Cannabinoids ameliorate CP/CPPS and reduce inflammation by degrading COX-2 in the microenvironment through the TLR4-NFκB inhibitory pathway. thus suggesting that cannabinoids may be a potential and promising approach for the treatment of CP/CPPS.
Source of Funding: